Benfotiamine is a synthetic, fat-soluble form of vitamin B1 (thiamine) that the body absorbs far more efficiently than standard thiamine supplements. In pharmacokinetic studies, oral benfotiamine delivered roughly 11 times more thiamine into the bloodstream than an equivalent dose of regular thiamine hydrochloride. Originally developed in Japan in the 1960s, it’s now widely available as a dietary supplement and is most commonly used by people with diabetes-related nerve problems.
How It Differs From Regular Thiamine
Standard thiamine (vitamin B1) dissolves in water, which limits how much your gut can absorb at once. There’s essentially a ceiling: once the body’s transport system is saturated, extra thiamine passes straight through. Benfotiamine sidesteps this bottleneck because its fat-soluble structure allows it to pass directly through cell membranes without relying on the same transport pathway.
Chemically, benfotiamine is created by opening thiamine’s ring structure and attaching a fat-friendly group. Once inside your cells, enzymes strip away that modification and convert it back into active thiamine. A pharmacokinetic study found that benfotiamine produced plasma thiamine levels about 11.5 times higher than the same oral dose of thiamine hydrochloride. It also nearly doubled the amount of the active thiamine form found inside red blood cells. In practical terms, this means you can achieve tissue-level thiamine concentrations with oral benfotiamine that would otherwise require injections of regular thiamine.
What It Does in the Body
Benfotiamine’s primary action is boosting the activity of an enzyme called transketolase. This enzyme plays a key role in how your cells process sugar. When blood sugar is chronically high, excess glucose gets funneled into several damaging chemical pathways that produce harmful byproducts, including compounds called advanced glycation end products (AGEs). AGEs are sticky, destructive molecules that damage blood vessels, nerves, and organs over time.
By ramping up transketolase, benfotiamine redirects excess sugar away from those harmful pathways and into a safer metabolic route. A landmark study published in Nature Medicine showed that benfotiamine blocked three major pathways of high-blood-sugar damage simultaneously and also suppressed a key inflammation trigger (NF-kappaB). In diabetic animals, this translated into measurable protection against retinal damage. This multi-pathway blocking is what sets benfotiamine apart from other approaches that typically target only one damaging mechanism at a time.
Diabetic Nerve Pain
The most studied use of benfotiamine is for diabetic polyneuropathy, the tingling, burning, and numbness that affects the feet and hands of many people with diabetes. The BENDIP trial, a randomized, double-blind, placebo-controlled study, tested benfotiamine at two different doses over six weeks. Patients taking the higher dose showed significant improvement in their Neuropathy Symptom Score compared to placebo, with pain showing the strongest response among individual symptoms. The benefit also appeared to grow the longer people took it.
Short-term studies lasting 3 to 12 weeks have generally used doses up to 600 mg per day for neuropathy symptoms. Longer-term research, including a 24-month trial in people with type 1 diabetes, used 300 mg per day. Results for nerve function in longer trials have been less dramatic, suggesting benfotiamine may help with symptoms like pain more reliably than it reverses the underlying nerve damage itself.
Cognitive Decline and Alzheimer’s Disease
One of the more intriguing areas of benfotiamine research involves Alzheimer’s disease. A phase IIa clinical trial gave benfotiamine or placebo to 70 people with mild cognitive impairment or mild Alzheimer’s for 12 months. The results were promising but preliminary. Cognitive decline on a standard dementia rating scale was 77% lower in the benfotiamine group compared to placebo, a statistically significant difference. On a broader cognitive test, decline was 43% lower, though that result narrowly missed statistical significance.
The trial also found that benfotiamine significantly reduced blood levels of AGEs and improved a brain imaging measure of glucose metabolism. The effects were strongest in people without the APOEε4 gene variant, the most common genetic risk factor for Alzheimer’s. Researchers described benfotiamine as safe and “potentially efficacious,” but emphasized that larger trials are needed before any clinical recommendations can be made. The connection to Alzheimer’s is still theoretical: the disease involves impaired brain glucose metabolism and AGE accumulation, both of which benfotiamine targets, but whether that translates into meaningful long-term protection remains unproven.
Where the Evidence Falls Short
Not every proposed benefit of benfotiamine has held up in human trials. A notable example is kidney disease. A double-blind, placebo-controlled trial gave 900 mg per day of benfotiamine to people with type 2 diabetes and early kidney damage for 12 weeks. Despite clearly improving thiamine levels in the blood, benfotiamine did not reduce urinary albumin excretion (a marker of kidney damage) or levels of a kidney injury molecule compared to placebo. The disconnect between strong preclinical results in animals and disappointing outcomes in humans is a recurring theme in benfotiamine research.
Similarly, while the neuropathy symptom improvements in short-term trials are encouraging, longer studies haven’t consistently shown that benfotiamine changes the trajectory of nerve damage as measured by nerve conduction tests and other objective measures. The gap between subjective symptom relief and measurable nerve repair is important to keep in mind.
Dosage Used in Research
Clinical trials have used a fairly consistent range of doses. For general supplementation and long-term use, 300 mg per day is the most common dose studied, including in the 24-month diabetes trial. For shorter-term treatment of neuropathy symptoms, doses up to 600 mg per day have been used over periods of 3 to 12 weeks. The Alzheimer’s trial used a higher dose over 12 months. Benfotiamine supplements are typically sold in 150 mg or 300 mg capsules.
Safety Profile
Across multiple clinical trials lasting up to two years, benfotiamine has shown a reassuring safety record. The 24-month trial using 300 mg daily in people with type 1 diabetes reported no significant safety concerns, and the 12-month Alzheimer’s trial at higher doses specifically described benfotiamine as safe. Because it converts to ordinary thiamine inside the body, and because excess water-soluble B vitamins are generally excreted in urine, the risk of toxicity appears low. That said, most trials have studied relatively small groups of people (typically 40 to 70 participants), so rare side effects could still be undetected. Benfotiamine is sold as a supplement, not a prescription drug, so it is not subject to the same regulatory oversight as medications in most countries.